Astex
  • Discover Astex
    • Our Mission & Values
    • Our Leadership Team
      • UK – Discovery Research
        • Jeremy Carmichael
        • Harren Jhoti
        • Michelle Jones
        • Neil Jones
        • John Lyons
        • Chris Murray
        • David Rees
        • Nicola Wallis
        • Nicola Wilsher
      • USA – Product Development
        • Mohammad Azab
        • Martin Buckland
        • Harold N. Keer
        • Nipun Davar
        • Yong Hao
        • Joseph Iovino
        • Samuel Jason
        • Nancy Worrell
        • Patti Oto
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Proprietary Products and Programs
        • Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
        • ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX727 Oral DNMT inhibitor (Hematological Malignancies)
        • ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • AZD5363 PKB/Akt Inhibitor (Oncology)
        • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation
  • Partnering
  • Our People
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Astex in the News
  • Contact
  • Search
  • Menu Menu
You are here: Home1 / 2013 ASH: First Clinical Results of a randomized Phase 2 study of SGI-110...

2013 ASH: First Clinical Results of a randomized Phase 2 study of SGI-110 in adult patients with AML

25 November 2013/in Uncategorised /by webadmin

2013 ASH: First Clinical Results of a randomized Phase 2 study of SGI-110 in adult patients with AML

/wp-content/uploads/2019/11/logo_white.png 0 0 webadmin /wp-content/uploads/2019/11/logo_white.png webadmin2013-11-25 15:52:172016-12-01 12:43:362013 ASH: First Clinical Results of a randomized Phase 2 study of SGI-110 in adult patients with AML

Copyright © Astex Pharmaceuticals
All rights reserved

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal

Member of the Otsuka Group

2013 WorldMelanoma: Combining AT13387 with vemurafenib delay emergence of resistance... 2013 ASH: Determinants of Demethylation and Clinical Response in AML patients...
Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok